Pharma

Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of Depemokimab and the...

All three tested Niktimvo dosing regimens led to statistically significant overall response rates in patients who have undergone allogenic hematopoietic...

Xdemvy is the first and only approved FDA treatment for Demodex blepharitis Xdemvy can achieve collarette reduction of no more...

Patients with chronic pain from osteoarthritis who received LEVI-04 had a 50% reduction in pain from baseline. LEVI-04 was well...

Treatment with BNT111 + cemiplimab showed a statistically significant overall response in patients with inoperable or advanced-stage anti-PD-1 refractory melanoma...

Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of...

Giroctocogene fitelparvovec, a novel gene therapy, demonstrated superiority to routine therapy in treating hemophilia A. Giroctocogene fitelparvovec resulted in a...

A dose-dependent slowing in Huntington's disease progression was observed after 24 months in patients receiving high-dose AMT-130. The gene therapy...

Jemperli in combination with chemotherapy showed a 31% reduction in the risk of death and a 16.4-month improvement in median...

83% of participants on an oral Sirturo-containing regimen achieved a favorable outcome compared to 71% of patients on the control...